PIII Financials | Income, Balance Sheet & Cash Flow

The financial statements for PIII (PIII) provide a snapshot of revenue trends, balance-sheet strength, and cash flow quality. Reviewing these together helps investors evaluate earnings durability, capital structure, and whether operating cash flow supports long-term business growth.

See stock fair value and complete historical financials—premium unlocks deeper tables and metrics.

Financial Statements

Related peers

Compare More →
ITRM
Iterum Therapeutics plc
$0.03
-10.98%
HYPD
Eyenovia, Inc. Common Stock
$4.46
+14.07%
TLPH
Talphera, Inc.
$0.80
-0.79%
IBIO
iBio, Inc.
$2.06
-2.37%
INTS
Intensity Therapeutics, Inc.
$5.30
-0.38%
BMGL
Basel Medical Group Ltd Ordinary Shares
$0.57
-4.82%

Frequently Asked Questions

What are PIII's latest financial results?

Review PIII's latest balance sheet, income statement, and cash flow to understand its profitability, revenue trends, and financial health. These metrics are essential for evaluating short-term performance and long-term stability.

How has PIII's revenue and net income changed over time?

Analyzing historical revenue and net income shows growth trends and business performance. Consistent growth indicates operational strength, while declines may signal challenges that investors should consider.

What is PIII's cash flow situation and liquidity?

Cash flow statements reveal how PIII generates and uses cash. Strong operating cash flow and sufficient liquidity suggest the company can fund operations, pay dividends, and handle debt effectively.

How does PIII's financial performance compare to industry peers?

Comparing key metrics like revenue growth, profit margins, and debt levels with competitors helps investors assess whether PIII is outperforming or lagging within its sector.

Are PIII's financial statements showing sustainable profitability?

By analyzing margins, ROE, ROIC, and cash generation over multiple periods, investors can evaluate whether PIII's profits are repeatable and supported by strong fundamentals.